The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction

Philip Cohen

MRC Protein Phosphorylation Unit, Department of Biochemistry, University of Dundee, Dundee DD1 5EH, UK

Diabetes affects 3% of the European population and 140 million people worldwide, and is largely a disease of insulin resistance in which the tissues fail to respond to this hormone. This emphasizes the importance of understanding how insulin signals to the cell's interior. We have recently dissected a protein kinase cascade that is triggered by the formation of the insulin 'second messenger' phosphatidylinositol (3,4,5) trisphosphate (PtdIns(3,4,5)P₃) and which appears to mediate many of the metabolic actions of this hormone. The first enzyme in the cascade is termed 3-phosphoinositide-dependent protein kinase-1 (PDK1), because it only activates protein kinase B (PKB), the next enzyme in the pathway, in the presence of PtdIns(3,4,5)P₃. PKB then inactivates glycogen synthase kinase-3 (GSK3). PDK1, PKB and GSK3 regulate many physiological events by phosphorylating a variety of intracellular proteins. In addition, PKB plays an important role in mediating protection against apoptosis by survival factors, such as insulin-like growth factor-1.

Keywords: insulin; IGF1; diabetes; protein kinase; apoptosis; inositol phospholipid

1. INTRODUCTION

Although it has been known for 100 years that proteins contain covalently bound phosphate, it was only in the mid-1950s that the biological significance of this phenomenon began to be recognized. Just over 40 years ago, Edmond Fischer and Edwin Krebs discovered that glycogen phosphorylase was regulated by reversible phosphorylation. This enzyme, which mobilizes glycogen for energy production during muscle contraction, is present in an inactive form in resting muscle, and is converted to an active form during contraction. Fischer and Krebs showed that activation involves the transfer of phosphate from ATP to a serine residue on glycogen phosphorylase, in a phosphorylation reaction catalysed by phosphorylase kinase, the first protein kinase to be identified. Phosphorylase kinase is activated by calcium ions, explaining how the mobilization of glycogen is coupled to the onset of muscle contraction (Cohen 1980). When contraction ceases, glycogen phosphorylase is reconverted to the inactive, dephosphorylated species by protein phosphatase-1 (Cohen 1978).

The general significance of these findings was not appreciated for many years and phosphorylation was still thought of as a control mechanism specific to the regulation of glycogen metabolism when I first started to work in this field in late 1969. The subsequent explosion of this area has therefore been remarkable, since it is now clear that the reversible phosphorylation of proteins regulates most aspects of cell life. Its functions include the control of metabolism, secretion, the expression of genes, the immune response, cell proliferation and differentiation, fertilization and even the acquisition of memory.

About one-third of mammalian proteins contain covalently bound phosphate, while protein kinases and phosphatases (together with a myriad of regulatory and targeting subunits that control and direct them to the correct subcellular locations (Hubbard & Cohen 1993; Egloff *et al.* 1997)) account for perhaps 5% of all human gene products. The phosphorylation of proteins on serine, threonine and tyrosine residues alters their shape and hence their ability to function. However, phosphorylation can affect the functioning of protein in other ways, for example by altering the rate at which they are degraded, or their ability to migrate from one cellular compartment to another. The simplicity, flexibility and reversibility of phosphorylation explains why this covalent modification has been adopted by eukaryotic cells as its major control mechanism.

2. REVERSIBLE PROTEIN PHOSPHORYLATION AND HUMAN DISEASE

In view its importance in cell regulation, it should come as no surprise to learn that abnormal protein phosphorylation is a cause or consequence of many diseases. For example, at least 15 hereditary disorders result from genetic alterations in various protein kinases and phosphatases. These include forms of muscular dystrophy, leukaemia and lymphoma, severe combined immunodeficiency syndromes and leprechaunism.

Several toxins and tumour promoters that are a threat to the health of man and his domestic livestock are inhibitors of phosphatases that dephosphorylate serine and threonine residues in proteins. These include okadaic acid (Cohen *et al.* 1990), the toxin responsible for diarrhetic

seafood poisoning (DSP), which is produced by marine micro-organisms and accumulates in the digestive glands of shellfish. This substance has not only poisoned many thousands of people (including in 1976 the President of the French Republic), but continues to have devastating effects on the shellfish industry worldwide, causing losses amounting to millions of pounds each year.

Another toxin that inhibits the same class of protein phosphatases is microcystin, a cyclic heptapeptide produced by toxic blue-green algae (MacKintosh *et al.* 1990, 1995). This substance is an extremely powerful hepatotoxin and the most potent liver carcinogen known to man. It poses a potential threat to water supplies because toxic algal blooms affect 75% of reservoirs worldwide, and this problem is becoming more serious because the growth of algae has accelerated as a result of the enrichment of water with nitrates from fertilizers and phosphates from detergents. Several years ago our Unit developed a simple method for measuring the level of microcystin, based on phosphatase inhibition, which is thousands of times more sensitive than those used previously (MacKintosh & MacKintosh 1994). This method has been adopted by the Thames Water Authority and several reservoirs were stopped from supplying water to the London area in 1994 because of the high level of microcystin detected by the use of this technique.

Several serious diseases, such as pseudotuberculosis and the bubonic plague, are caused by bacteria of the genus *Yersinia*. The bubonic plague has been responsible for pandemics such as 'the Black Death', which killed one-quarter of the population of Europe and 42 million people worldwide in the 12th and 13th centuries. The essential virulence agent for these diseases is a protein phosphatase encoded in the genome of *Yersinia* (Bliska *et al.* 1991), which causes the uncontrolled tyrosine dephosphorylation of many proteins and leads rapidly to death.

The abnormal phosphorylation of proteins is also the cause or consequence of major diseases such as cancer, inflammation and diabetes. However, before discussing recent progress in understanding how cells respond to insulin, which is defective in diabetes, I must first briefly introduce the concept of 'signal transduction'.

3. PROTEIN PHOSPHORYLATION AND SIGNAL TRANSDUCTION

Signal transduction is the process by which cells respond to extracellular agonists, such as hormones, growth factors and cytokines. These substances circulate in the blood at nanomolar concentrations (or even lower) and yet, without entering their target cells, they can elicit remarkable alterations in cell behaviour on the seconds-to-minutes time-scale. The generalized mechanism by which this is achieved is illustrated schematically in figure 1. Signals bind to specific receptors on the outer surface of the cell membrane, triggering the activation of trans-membrane signalling systems that control the production of chemical mediators termed 'second messengers'. These substances regulate the activities of protein kinases and phosphatases, thereby altering the level of phosphorylation of intracellular proteins. The effect of a signal is amplified enormously through these devices, and since each 'second messenger'-dependent protein kinase (or

Figure 1. Generalized signal transduction pathway by which hormones and other extracellular signals regulate cell functions.

phosphatase) normally catalyses the phosphorylation (or dephosphorylation) of many intracellular proteins, this explains how any one signal can produce such a diversity of responses (Cohen 1982, 1985). The amplification and diversity of a response are frequently enhanced when several protein kinases become linked together in a sequence to form a protein kinase 'cascade'. In these situations, each protein kinase in the cascade can also become a target for regulation by other protein kinases and phosphatases that are themselves controlled by different signals, leading to signal integration. Moreover, once activated, protein kinases can migrate to different regions of the cell, allowing the signal to 'reach' different compartments. The MRC Protein Phosphorylation Unit is involved in dissecting a number of protein kinase cascades the activation of which is abnormal in major diseases like cancer, arthritis and diabetes. In this paper I concentrate on the last of these three topics.

4. INSULIN AND DIABETES

Insulin is a protein produced and secreted by the β -cells of the pancreas, whose principal functions are to regulate the uptake of nutrients (glucose, amino acids, fatty acids) and the production of storage macromolecules (protein, glycogen, triglycerides) by muscle, liver and adipose tissue. Diabetes is characterized by the failure to synthesize, secrete or respond to insulin and is the third most prevalent disease in the Western world. It affects some 3% of the population of Europe and North America and 140 million worldwide. However, due to long-term complications, such as increased risk of heart disease, kidney failure and blindness, the treatment of diabetes was estimated to account for 12% of total health-care expenditure in the USA in 1992. In most people with diabetes, the level of insulin in the circulation is normal, or even above normal, at least in the early stages of the disease, and the primary defect is the failure of the tissues to respond to this hormone. To understand the causes of diabetes, and hence to be able to improve its

Figure 2. Cartoon drawn by Pierre de Metz and published in *Trends in Biochemical Sciences* in 1979 that summarized the lack of progress in understanding insulin signal transduction at that time. It was known that insulin interacted with a specific receptor in the plasma membrane, but how this led to the physiological effects of the hormone was obscure.

treatment, it is therefore critical to elucidate the mechanism by which insulin signals to the cell interior. However, the solution to this apparently simple problem has proved to be remarkably elusive. The Nobel Prize for Medicine was awarded in 1923 for the discovery of insulin a couple of years earlier by George Banting and Charles Best (the 1955 Croonian Lecturer), while Fred Sanger (the 1975 Croonian Lecturer) and Dorothy Hodgkin were awarded the 1958 and 1964 Nobel Prizes for Chemistry for elucidating its amino acid sequence and three-dimensional structure. However, the insulin signalling mechanism remained unsolved for over 50 years. A famous cartoon from 1979 reproduced in figure 2 nicely summarized how little we knew about this process 18 years ago.

5. FROM THE INSULIN RECEPTOR TO THE FORMATION OF PHOSPHATIDYLINOSITIDE (3,4,5) TRISPHOSPHATE

Real progress in understanding insulin signal transduction started to be made in the early 1980s. Ron Kahn discovered that the insulin receptor (Kasuga *et al.* 1982), like the epidermal growth factor receptor (Ushiro & Cohen 1980), was a protein tyrosine kinase, and he and Morris White identified the insulin receptor substrate proteins (IRS) (Myers *et al.* 1994; Sun *et al.* 1995) as key targets of the receptor. The phosphotyrosine residues on IRS proteins then interact with the SH2-domain (Pawson & Gish 1992) of the p85 regulatory subunit of class 1 phosphatidylinositol (PtdIns) 3-kinases, thereby recruiting the latter to the plasma membrane. Class 1 PtdIns 3-kinases, first described by Lew Cantley (Whitman *et al.* 1988), then phosphorylates a minor inositol phospholipid in the plasma membrane, termed PtdIns (4,5) bisphosphate at the D-3 position of the inositol ring to produce PtdIns (3,4,5) trisphosphate (PtdIns(3,4,5)P₃) (Vanhaesbroeck *et al.* 1997) (figure 3), which is subsequently converted to PtdIns(3,4)P₂ by the

Figure 3. Molecular mechanism by which insulin stimulates the formation of PtdIns(3,4,5)P₃. Insulin binds to the α -subunit of the insulin receptor, activating the protein tyrosine kinase associated with the β -subunit. The β -subunit then phosphorylates itself at a number of residues, including Tyr-960. The phosphorylation of Tyr-960 triggers an interaction between the receptor and isoforms of the insulin receptor substrate (IRS), allowing the receptor to phosphorylate IRS at multiple tyrosine residues. Particular phosphotyrosine residues in IRS proteins then interact with the SH2 domain of the p85 subunit of class 1 PtdIns 3-kinases, thereby recruiting the p110 catalytic subunit to the plasma membrane where it converts the inositol phospholipid PtdIns(4,5)P₂ to PtdIns(3,4,5)P₃. PtdIns(3,4,5)P₃ is subsequently converted to PtdIns(3,4)P₂ by a specific 5'-phosphatase.

action of a 5'-phosphatase(s) (Woscholski & Parker 1997). The level of PtdIns(3,4,5)P₃ *in vivo* increases 10- to 100-fold within 30 s of stimulation with insulin, followed by a similar rise in PtdIns(3,4)P₂ (Vanhaesbroeck *et al.* 1997; Woscholski & Parker 1997). The importance of PtdIns 3-kinases in insulin signal transduction became clear when inhibitors of these enzymes, wortmannin (Ui *et al.* 1995) and LY 294002 (Vlahos *et al.* 1994), were shown to suppress nearly all the metabolic actions of insulin. This suggested that PtdIns(3,4,5)P₃ or a metabolite derived from it, such as PtdIns(3,4)P₂, might be the long sought after 'second messenger' for insulin, raising the question of how this compound exerted its effects on cell function.

6. THE STIMULATION OF GLYCOGEN SYNTHESIS BY INSULIN

Two approaches can be employed to elucidate signal transduction pathways. One way is to start from the receptor at the plasma membrane and to work step by step from the outside to the inside of the cell, while the second is to select a physiological action of the hormone and then work backwards towards the receptor. The latter method was exploited by Earl Sutherland (the 1970 Nobel Laureate for Medicine) when he discovered that cyclic AMP (the original second messenger) mediates the adrenergic stimulation of glycogenolysis (Robison *et al.* 1971), and is the approach that we have adopted.

We selected glycogen synthesis in skeletal muscle as our model system in the early 1970s because it was the only one where any biochemical information was available about insulin signal transduction. In the early 1960s, Joe Larner and his colleagues had discovered that glycogen synthase, the enzyme that catalyses the last step in the synthesis of glycogen, was inactivated by phosphorylation and reactivated by dephosphorylation (Friedman & Larner 1963). Larner also showed that insulin stimulates

Figure 4. Glycogen synthase in rabbit skeletal muscle is phosphorylated on nine serine residues *in vivo* by at least six protein kinases. The nine serine residues are located at residues 7 (site 2a), 10 (2b), 640 (3a), 644 (3b), 648 (3c), 652 (4), 656 (5), 697 (1a) and 710 (1b). Abbreviations: PKA, cyclic AMP-dependent protein kinase; PhK, phosphorylase kinase; CaM-K2, calmodulin-dependent protein kinase-2; CK1, casein kinase-1; GSK3, glycogen synthase kinase-3; CK2, casein kinase-2. Most of the phosphate released from glycogen synthase in response to insulin is removed from the tryptic peptide containing sites 3a, 3b and 3c.

glycogen synthase by promoting its dephosphorylation (Craig & Larner 1964), the first time any enzyme had been shown to be regulated by this hormone. It was therefore obvious that insulin must exert its effect via inhibition of a protein kinase and/or activation of a protein phosphatase. Cyclic AMP-dependent protein kinase (PKA) was identified in 1968 (Walsh *et al.* 1968) and shown to phosphorylate and inhibit glycogen synthase *in vitro* (Schlender *et al.* 1969; Soderling *et al.* 1970). This finding suggested that the inhibition of PKA might underlie the insulin-induced activation of glycogen synthase, but the level of cyclic AMP in skeletal muscle was not affected by insulin (Craig & Larner 1964).

Our work on this problem was initiated in late 1973 and within months we had discovered another protein kinase that phosphorylated glycogen synthase at a residue distinct from that targeted by PKA (Nimmo & Cohen 1974). We (and others) then identified further glycogen synthase kinases, but the full complexity of the situation was only revealed many years later when it became clear that glycogen synthase is phosphorylated at nine serine residues *in vivo* by a minimum of six protein kinases (Poulter *et al.* 1988; Nakielnny *et al.* 1991) (figure 4). In 1983, we showed that the insulin-induced dephosphorylation of glycogen synthase occurred mainly at serine residues phosphorylated by glycogen synthase kinase-3 (GSK3) (Parker *et al.* 1983), an enzyme that we had identified a few years earlier (Embi *et al.* 1980; Rylatt *et al.* 1980). These observations implied that the inhibition of PKA did not underlie the stimulation of glycogen synthase by insulin. Rather, it appeared that insulin must either induce a decrease in GSK3 activity and/or activate protein phosphatase-1, the enzyme that dephosphorylates these sites.

7. THE INHIBITION OF GSK3 BY INSULIN IS LIKELY TO BE MEDIATED BY PROTEIN KINASE B

The discovery that GSK3 is inhibited by insulin was made by investigators studying the mechanism by which insulin stimulates fatty acid synthesis and protein synthesis. Bill Benjamin identified a 'multifunctional' protein

kinase that phosphorylated a number of proteins including ATP-citrate lyase, the enzyme that converts citrate to acetyl CoA. The activity of the kinase decreased when adipocytes were stimulated for a few minutes with insulin, and this enzyme was subsequently identified by Jim Woodgett as the α -isoform of GSK3 (Hughes *et al.* 1992). Chris Proud described an insulin-inhibited protein kinase that phosphorylated eIF2B, a guanine nucleotide exchange factor essential for the initiation of protein synthesis; this protein kinase was identified as the β -isoform of GSK3 (Welsh & Proud 1993). Subsequently, we showed that insulin decreases the activities of both GSK3 isoforms in skeletal muscle (Cross *et al.* 1994, 1997).

In unstimulated cells, GSK3 is phosphorylated stoichiometrically at one tyrosine residue (Tyr-279 in the GSK3 α isoform and Tyr-216 in GSK3 β) and the dephosphorylation of these residues *in vitro* is accompanied by inactivation (Hughes *et al.* 1993). It had therefore been suggested that the inhibition of GSK3 by insulin might result from activation of a protein tyrosine phosphatase. However, the insulin-induced inhibition of both GSK3 isoforms could be reversed by the serine-threonine-specific protein phosphatases, implying that inhibition was caused by increased serine or threonine phosphorylation and not by decreased tyrosine phosphorylation (Welsh & Proud 1993; Cross *et al.* 1994). We established, subsequently, that this was indeed the case and that the inactivating phosphorylations occur at Ser21 (GSK3 α) and Ser9 (GSK3 β) (Cross *et al.* 1995; Shaw *et al.* 1997).

We initially identified two insulin-stimulated protein kinases that phosphorylated GSK3 α at Ser-21 and GSK3 β at Ser-9 (Sutherland *et al.* 1993; Sutherland & Cohen 1994). One was MAP kinase-activated protein kinase-1 (MAPKAP-K1, also known as p90^{msk}), a component of the classical MAP kinase cascade, while the other was p70 S6 kinase. The insulin-induced activation of the MAP kinase cascade, and hence the activation of MAPKAP-K1, can be prevented by prior exposure of cells to the drug PD 98059 (Alessi *et al.* 1995), while the activation of p70 S6 kinase can be prevented by the immunosuppressant drug rapamycin (Chung *et al.* 1992). We therefore used these compounds to try and determine which insulin-stimulated protein kinase mediated the inhibition of GSK3 by insulin. Surprisingly, these and other experiments revealed that neither MAPKAP-K1 nor p70 S6 kinase were rate limiting for the inhibition of GSK3 by insulin (Cross *et al.* 1995). However, inhibition was suppressed by inhibitors of PtdIns 3-kinase (Cross *et al.* 1995), indicating that GSK3 was inactivated by a novel insulin-stimulated protein kinase whose activation was dependent on PtdIns 3-kinase.

To identify the relevant insulin-stimulated protein kinase(s), we subjected lysates from L6 cells to anion exchange chromatography and assayed the fractions for protein kinases capable of phosphorylating a synthetic peptide related to the amino acid sequence surrounding Ser21 in GSK3 α and Ser9 in GSK3 β (Cross *et al.* 1995). We called this peptide 'Crosstide' after Darren Cross, the PhD student who was carrying out these experiments. These studies revealed three major peaks of Crosstide kinase activity which had the properties we were looking for, i.e. they could only be detected if the cells were

stimulated with insulin, and their appearance was prevented if the cells were preincubated with inhibitors of PtdIns 3-kinase, but not if the cells were preincubated with PD 98059 and rapamycin. It looked as though we would now have to spend a considerable time purifying and characterizing these protein kinases but, at this juncture, a stroke of luck occurred with the arrival of Brian Hemmings from Basel to examine one of my wife's PhD students. After telling Brian about our results, he informed us that an enzyme termed protein kinase B (PKB) had just been shown to be activated by insulin and other growth factors via a PtdIns 3-kinase-dependent mechanism (Franke *et al.* 1995; Burgering & Coffey 1995). PKB had been cloned several years earlier by Brian while he was searching for novel homologues of PKA, and by Jim Woodgett who had been trying to detect novel isoforms of protein kinase C (PKC). Brian had called it RAC (related to A and C) kinase (Jones *et al.* 1991), while Jim had used the name protein kinase B (PKB) because it was similar (in between) PKA and PKC (Coffey & Woodgett 1991). The name PKB is used hereafter to avoid any confusion with the GTP-binding protein RAC.

Fortunately, Brian had raised an immunoprecipitating antibody to the α -isoform of PKB, so that we were able to show very rapidly that two of the peaks of Crosstide kinase activity corresponded to PKB α (Cross *et al.* 1995); more recently the other peak of Crosstide kinase activity was identified as PKB γ (Walker *et al.* 1998).

We showed that PKB phosphorylates each GSK3 isoform *in vitro* and at the relevant serine residues (Cross *et al.* 1995), and several further lines of evidence were consistent with PKB lying 'upstream' of GSK3 *in vivo*. First, PKB is activated by insulin with a half-time of 1 min, slightly faster than the inhibition of GSK3, which occurs with a half-time of 2 min (Cross *et al.* 1995, 1997). Second, GSK3 is inhibited when cotransfected into mammalian cells with PKB, or with PDK1 (one of the activators of PKB; see below) (Shaw *et al.* 1997). It was therefore clear that we now needed to find out how PKB was activated.

8. PROTEIN KINASE B IS ACTIVATED BY PHOSPHORYLATION; IDENTIFICATION OF PDK1

The activated form of PKB α can be inactivated by PP2A, but not by protein tyrosine phosphatases (Cross *et al.* 1995; Andjelkovic *et al.* 1996), suggesting that activation is triggered by phosphorylation of a serine and/or threonine residue(s). We found that the activation of PKB α in L6 myotubes induced by either insulin or insulin-like growth factor-1 (IGF1) was accompanied by the phosphorylation of Thr308 in the catalytic domain and Ser473 close to the C-terminus. Several lines of evidence showed that the phosphorylation of either residue produced partial activation, that the phosphorylation of both residues was required for full activation and that neither site was phosphorylated by PKB α itself (Alessi *et al.* 1996a).

There are three isoforms of PKB. PKB β is activated by the phosphorylation of Thr309 and Ser474, the residues equivalent to Thr308 and Ser473 of PKB α (Meier *et al.* 1997), but PKB γ is activated solely by the phosphoryla-

tion of Thr395, the residue equivalent to Thr308 (Walker *et al.* 1998) because it terminates at residue 454 and therefore lacks Ser473 of PKB α .

The insulin-induced or IGF1-induced phosphorylation of Thr-308 and Ser-473, like the activation of PKB, is prevented by inhibitors of PtdIns 3-kinase (Alessi *et al.* 1996), suggesting that the protein kinase(s) responsible for phosphorylating PKB at these sites might require PtdIns(3,4,5)P₃ for activity. These observations led us to detect a protein kinase that phosphorylates PKB α at Thr308 (Alessi *et al.* 1997a), PKB β at Thr309 and PKB γ at Thr305 (Walker *et al.* 1998), only in the presence of lipid vesicles containing micromolar concentrations of PtdIns(3,4,5)P₃ or PtdIns(3,4)P₂. We therefore termed this enzyme 3-phosphoinositide-dependent protein kinase-1 (PDK1).

We purified PDK1 to near homogeneity (Alessi *et al.* 1997b) and after sequencing a number of tryptic peptides used them to interrogate protein sequence databases. This allowed almost the entire sequence to be assembled from ESTs, and revealed that PDK1 comprises an N-terminal catalytic domain and a C-terminal pleckstrin homology (PH) domain (Alessi *et al.* 1997b). It is therefore the 'mirror image' of PKB, in which a PH domain precedes the catalytic domain. The database search also revealed that, surprisingly, the nucleotide sequence encoding a *Drosophila* homologue of PDK1 had also recently been deposited in the database. Even more surprisingly, it had been deposited by another investigator (Mary Bownes) working in Scotland. I return to this near the end of the paper.

9. ROLE OF 3-PHOSPHOINOSITIDES IN THE PDK1-MEDIATED ACTIVATION OF PKB

The activation of PKB is stereospecific for the D-enantiomers of PtdIns(3,4,5)P₃, and the naturally occurring form (the 1-stearoyl, 2-arachidonoyl derivative) is more effective than the dipalmitoyl derivative (Alessi *et al.* 1997a). Since unsaturated fatty acids discourage tight packing of adjacent phospholipid molecules, this arrangement may allow for more efficient interaction between PtdIns(3,4,5)P₃ and/or PtdIns(3,4)P₂ and their protein effectors, perhaps explaining why inositol phospholipids have such unusual fatty acid compositions. Neither PtdIns(4,5)P₂ nor any other inositol phospholipid tested can replace PtdIns(3,4,5)P₃ or PtdIns(3,4)P₂ in the PDK1-catalysed activation of PKB. PKB itself is not activated (or inhibited) directly by any inositol phospholipid.

The findings described above gave rise to the name PDK1 (3-phosphoinositide-dependent protein kinase-1) (Alessi *et al.* 1997a), but subsequent work indicated that the requirement for PtdIns(3,4,5)P₃ or PtdIns(3,4)P₂ is mediated, at least in part, by the interaction of these inositol phospholipids with the PH domain of PKB. These 'second messengers' appear to alter the conformation of PKB so that Thr308 becomes accessible to PDK1. This conclusion is supported by the observation that a PKB α mutant that cannot interact with PtdIns(3,4,5)P₃ is not phosphorylated by PDK1 (Alessi *et al.* 1997b), and by the finding that PKB α lacking the PH domain is phosphorylated by PDK1 independently of PtdIns(3,4,5)P₃ or PtdIns(3,4)P₂ (Stokoe *et al.* 1997; Alessi *et al.* 1997b).

Consistent with this model, $\text{PtdIns}(3,4,5)\text{P}_3$ is still required for the activation of $\text{PKB}\alpha$ by a truncated form of PDK1 that lacks the C-terminal PH domain (Stokoe *et al.* 1997).

The PH domains of PKB (James *et al.* 1996) and PDK1 (Currie *et al.* 1999) both bind $\text{PtdIns}(3,4,5)\text{P}_3$, $\text{PtdIns}(3,4)\text{P}_2$ and $\text{PtdIns}(4,5)\text{P}_2$ *in vitro*, and PDK1 appears to interact with these inositol phospholipids more strongly than PKB. Moreover, the rate of activation of $\text{PKB}\alpha$ is reduced about 30-fold if the PH domain of PDK1 is deleted (Alessi *et al.* 1997b) or mutated so that it cannot bind $\text{PtdIns}(3,4,5)\text{P}_3$. These observations suggest that the PH domain of PDK1 plays an important role in the activation process by localizing this enzyme to the same lipid vesicles as PKB.

10. RECRUITMENT TO THE PLASMA MEMBRANE IS SUFFICIENT TO TRIGGER THE PHOSPHORYLATION AND ACTIVATION OF PKB

$\text{PKB}\alpha$ is located in the cytosol of unstimulated cells, but rapidly translocates to the plasma membrane following cell stimulation with IGF1 (Andjelkovic *et al.* 1997) and other agonists (Ahmed *et al.* 1997; Wijkander *et al.* 1997). Translocation is prevented by inhibitors of PtdIns 3-kinase or if the PH domain of PKB is deleted (Andjelkovic *et al.* 1997). Moreover, attachment of a membrane-targeting sequence to the N-terminus of $\text{PKB}\alpha$ is sufficient to induce maximal activation of PKB (Kohn *et al.* 1996), and its phosphorylation at Thr308 and Ser473 (Andjelkovic *et al.* 1997), in unstimulated cells. These findings suggest that a key role of $\text{PtdIns}(3,4,5)\text{P}_3$ and/or $\text{PtdIns}(3,4)\text{P}_2$ in the activation of PKB is to recruit this enzyme to the plasma membrane where it is phosphorylated by PDK1 and by an as yet unidentified Ser473 kinase (hereafter termed PDK2). Consistent with this mechanism, a significant proportion of the PDK1 localizes to the plasma membrane (even in unstimulated cells) when overexpressed in human embryonic kidney 293 cells (Currie *et al.* 1999). This membrane association may reflect the ability of PDK1 to bind inositol phospholipids more strongly than PKB.

In summary, $\text{PtdIns}(3,4,5)\text{P}_3$ and/or $\text{PtdIns}(3,4)\text{P}_2$ appear to play three roles in the activation of PKB. First, they alter the conformation of PKB so that the phosphorylation sites become accessible to PDK1 and PDK2. Second, they recruit PKB to the plasma membrane where PDK1 and PDK2 are located (figure 5). Third, they bind to PDK1 and may facilitate the activation of PDK1 (and perhaps PDK2) *in vivo*.

11. EVIDENCE THAT THE PDK1-PKB-GSK3 CASCADE MEDIATES MANY OF THE METABOLIC ACTIONS OF INSULIN

With the discovery of PDK1, the two different approaches used to dissect the insulin signal transduction pathway (the 'outside to inside' and 'inside to outside' approaches) have finally met one another to produce, in outline, a pathway that is likely to contribute to the stimulation of glycogen synthesis by insulin. However, evidence is now accumulating which suggests that the PDK1-PKB-GSK3 'cascade' may play a much wider role and mediate many of the metabolic actions of insulin.

Figure 5. The mechanism of activation of PKB. The stimulation of cells with insulin or a survival factor, such as IGF1, activates PtdIns 3-kinase and elevates the level of $\text{PtdIns}(3,4,5)\text{P}_3$ at the plasma membrane. $\text{PtdIns}(3,4,5)\text{P}_3$ and/or its immediate breakdown product $\text{PtdIns}(3,4)\text{P}_2$ then interacts with the PH domain of PKB, which has two effects. First, it alters the conformation of PKB in such a way that Thr308 and (perhaps) Ser473 become accessible for phosphorylation by PDK1 and PDK2, respectively. Second, PKB is recruited from the cytosol to the plasma membrane where PDK1 and PDK2 are located. The phosphorylation of PKB at Thr308 and Ser473 (indicated by the circled letter Ps) activates PKB.

GSK3 phosphorylates numerous proteins *in vitro* at serine or threonine residues, and the inhibition of GSK3 by insulin is therefore likely to induce the dephosphorylation of numerous proteins *in vivo*. In particular, the inhibition of GSK3 appears to underlie the insulin-induced dephosphorylation and activation of eIF2B and may therefore contribute to the stimulation of protein synthesis (Welsh & Proud 1993), as well as glycogen synthesis (figure 6). GSK3 phosphorylates IRS-1 *in vitro*, impairing the ability of the insulin receptor to phosphorylate IRS-1 at tyrosine residues (Eldar-Finkelmann & Krebs 1997). This could represent a feedback activation loop for enhancing the insulin signal, but more work is needed to establish whether it really operates *in vivo*.

PKB phosphorylates serine and threonine residues in proteins and peptides that lie in Arg-Xaa-Arg-Yaa-Zaa-Ser/Thr-Hyd motifs, where Xaa is any residue, Yaa and Zaa are small side chains other than Gly, and Hyd is a bulky hydrophobic residue such as Phe or Leu (Alessi *et al.* 1996b). This motif not only surrounds the serine

Figure 6. The PDK1–PKB–GSK3 cascade may mediate many of the metabolic effects of insulin. The steps involved in the formation of PtdIns(3,4,5) P_3 are shown schematically in figure 3. The transfection of 3T3-L1 adipocytes and L6 myotubes with a constitutively active form of PKB mimics the action of insulin on glucose and amino acid transport, but how PKB mediates these effects is unknown.

residues in GSK3 α and GSK3 β , whose phosphorylation is induced by insulin, but also the serines whose phosphorylation underlies the insulin-induced activation of the cardiac isoform of 6-phosphofructo-2-kinase (PFK2). These residues are phosphorylated by PKB *in vitro*, and their phosphorylation *in vivo* is prevented by inhibitors of PtdIns 3-kinase (but not by rapamycin and PD 98059) (Lefebvre *et al.* 1996; Deprez *et al.* 1997). PFK2 catalyses the formation of fructose 2, 6 biphosphate, an allosteric activator of 6-phosphofructo-1-kinase (PFK1), which is the rate-limiting enzyme in glycolysis. Thus the phosphorylation of PFK2 by PKB probably explains how insulin stimulates glycolysis in the heart (figure 6). In

transfection-based experiments, PKB also mimics other actions of insulin, such as the enhancement of glucose uptake in adipocytes (Kohn *et al.* 1996) and L6 myotubes (Hajdich *et al.* 1998) that results from the translocation of GLUT4 from an intracellular compartment to the plasma membrane, as well as the increased rate of amino acid uptake into L6 myotubes (Hajdich *et al.* 1998).

The recent finding that the activation of PKB α (Andjelkovic *et al.* 1997) and PKB β (Meier *et al.* 1997) by IGF1 involves first their recruitment to the plasma membrane and then their translocation to the nucleus suggests that PKB may also have nuclear targets, such as transcription factors. This is supported by the finding that, in transfection-based experiments, PKB mimics the ability of insulin to induce the expression of leptin, the obesity gene product (Barthel *et al.* 1997).

12. OTHER PROTEIN KINASES ARE LIKELY TO BE SUBSTRATES FOR PDK1 AND PDK2 *IN VIVO*

Thr308 of PKB α lies between kinase subdomains VII and VIII, while Ser473 is situated beyond the catalytic domain in a Phe-Xaa-Xaa-Phe-Ser/Thr-Phe/Tyr motif. Amino acid sequences similar to those surrounding Thr308 and Ser473 are found in many protein kinases that play important roles in cell signalling, such as the isoforms of PKC (Newton 1995), Rho-dependent protein kinases (ROK) (Leung *et al.* 1996) and p70 S6 kinase (p70S6K) (Pullen & Thomas 1997) (figure 7). Moreover, the residues equivalent to Thr308 and Ser473 are nearly always separated by 160–165 amino acids. It is therefore tempting to speculate that these protein kinases are all phosphorylated by PDK1, PDK2 or closely related enzymes. For example, agonists that activate phospholipase C γ elevate the level of diacylglycerol, which interacts with PKCs recruiting them to the plasma membrane where they may be phosphorylated by PDK1 and/or PDK2. Diacylglycerol binding may also change the conformation of PKC isoforms so that they become accessible to PDK1 and PDK2. Similarly, the binding of GTP-Rho to ROK may permit phosphorylation by PDK1 and PDK2. In this scenario, PKB, PKC and ROK would all be regulated by analogous mechanisms in which their interaction with an effector would make the phosphorylation sites accessible to PDK1 and PDK2 as well as promoting recruitment to the plasma membrane where these activating kinases seem to be located.

Figure 7. Alignment of the phosphorylation site sequences of PKB α with the corresponding regions of p70 S6 kinase (p70S6K), PKC α , Rho-dependent protein kinase α (ROK α) and the N-terminal kinase domain of MAPKAP-K1a (also known as p90^{rsk}). Conserved amino acids surrounding the residues equivalent to Thr308 and Ser473 of PKB α are shown in bold type. p70 S6 kinase, PKC α and MAPKAP-K1a are known to be phosphorylated *in vivo* at the residues equivalent to Thr308 and Ser473 of PKB α . It is speculated that these residues are phosphorylated by PDK1, PDK2 or closely related enzymes.

PDK1 has recently been shown to phosphorylate p70S6K at Thr252 (Alessi *et al.* 1998), the residue equivalent to Thr308 of PKB α (figure 7). The phosphorylation of Thr252 activates p70 S6 kinase partially, but activation is greatly enhanced if Thr412 (the residue equivalent to Ser473 of PKB α) is mutated to Glu. This suggests that, as in PKB, the phosphorylation of both sites is required for the full activation of p70S6K. p70S6K mediates the insulin-induced phosphorylation of ribosomal protein S6, whose phosphorylation has been implicated in stimulating the translation of mRNA transcripts which contain a polypyrimidine tract at their 5' transcriptional start site; these transcripts mainly encode ribosomal proteins and protein synthesis elongation factors (Jeffries *et al.* 1994).

13. PKB AND THE PREVENTION OF APOPTOSIS

PKB is the cellular homologue of a viral oncogene v-Akt, a protein kinase encoded in the genome of a transforming retrovirus isolated from a rodent T-cell lymphoma (Belacossa *et al.* 1991). The finding that overexpression of v-Akt is required to maintain the transformed state, that PKB β is overexpressed in about 15% of ovarian cancers (Cheng *et al.* 1992) and 12% of pancreatic cancers (Cheng *et al.* 1996), and that PKB α is overexpressed in about 3% of breast cancers (Bellacossa *et al.* 1995), indicates that PKB has the potential to become oncogenic in high copy number. One reason for this is that PKB provides a signal that protects cells from apoptosis induced by a number of agents and this may explain why the overexpression of PKB enables cancer cells to survive and proliferate in the absence of survival factors, in situations where cells expressing normal levels of PKB would undergo apoptosis (reviewed in Marte & Downward 1997).

One of the cellular targets that PKB may phosphorylate to protect cells from apoptosis is BAD (Datta *et al.* 1997). This protein, in its dephosphorylated form, interacts with the Bcl family member Bcl_{XL} and induces apoptosis of some cells. However, after BAD is phosphorylated at Ser 136 by PKB, it dissociates from Bcl_{XL} and apoptosis is prevented (Datta *et al.* 1997). Ser136 lies in an Arg-Xaa-Arg-Xaa-Xaa-Ser motif. However, BAD has a restricted tissue distribution, suggesting that PKB may be able to arrest the apoptotic pathway in other ways.

A gene encoding a *Drosophila* homologue of PDK1 (termed DSTPK61) (Alessi *et al.* 1997b) was identified by Mary Bownes at the University of Edinburgh because it is differentially spliced in male and female *Drosophila* giving rise to transcripts that have the same coding sequence but different 5' and 3' untranslated regions. The levels of these transcripts vary in different tissues of male and female flies implying that the level of expression of the PDK1 protein varies in these cells in a sex-specific manner. The lower level of expression of PDK1 may result in a lower level of activation of PKB, raising the intriguing possibility that such cells may undergo more rapid apoptosis. It is tempting to speculate that this mechanism could underlie certain sexual characteristics. For example, male *Drosophila* develop a special muscle for holding the female abdomen during mating. This muscle is not produced in females because the progenitor cells undergo apoptosis at an early stage of development. This may result from a low level of expression of DSTPK61.

14. THE DEVELOPMENT OF SPECIFIC PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OTHER DISEASES

The idea that inhibitors of protein kinases and phosphatases might be used therapeutically only became a reality in 1991, with the discovery by Stuart Schreiber of how cyclosporin acted to suppress the immune system. This drug, which has revolutionized approaches to organ transplantation, binds to an intracellular protein, termed cyclophilin, and the cyclosporin-cyclophilin complex then inhibits a protein phosphatase, termed PP2B or calcineurin (Liu *et al.* 1991), that had been identified in my laboratory ten years earlier (Stewart *et al.* 1982). More recently, several specific protein kinase inhibitors with therapeutic potential have been developed. These include PD 98059, developed by Alan Saltiel and his colleagues at Parke-Davis, which inhibits the growth factor-stimulated MAP kinase cascade by preventing the activation of MAP kinase kinase (Alessi *et al.* 1995). PD 98059 causes reversion of the transformed phenotype of many Ras-transformed cell lines (Dudley *et al.* 1995), suggesting that more potent inhibitors of the MAP kinase pathway may be of value in the treatment of cancer. Another compound SB 203580, developed by John Lee, Peter Young and their colleagues at SmithKline Beecham, suppresses the production and some of the actions of pro-inflammatory cytokines and, in animal models, is efficacious in the treatment of inflammatory conditions such as rheumatoid arthritis (Badger *et al.* 1996). This compound is a specific inhibitor of a MAP kinase family member termed SAPK2a/p38 (Cohen 1997).

Drugs that modulate the PDK1-PKB-GSK3 cascade have yet to be developed. However, specific inhibitors of GSK3, or compounds that stimulate the PDK1-dependent activation of PKB by mimicking the action of PtdIns(3,4,5)P₃, may well be efficacious in the treatment of diabetes. Conversely, specific inhibitors of PKB β that do not inhibit other PKB isoforms may be effective in the treatment of ovarian and pancreatic cancer, because they may cause these cancer cells to apoptose. A specific inhibitor of PKB β is unlikely to cause diabetes because PKB α is the dominant isoform in skeletal muscle and liver and it is also a significant isoform in adipose tissue (Walker *et al.* 1998).

A Division of Signal Transduction Therapy has recently been set up in the Biochemistry Department at Dundee with the backing of five major pharmaceutical companies. One of its major aims is to facilitate the development of many more specific inhibitors of protein kinases and phosphatases with therapeutic potential for the treatment of many diseases, including diabetes. Like, PD 98059, rapamycin and SB 203580, these inhibitors are likely to become invaluable reagents for identifying the physiological roles of particular protein kinases and the signal transduction pathways in which they operate.

I thank the postgraduate students, postdoctoral fellows and collaborators who have contributed to the work of my laboratory over the past 27 years. I am indebted to Michael Rosemeyer (my PhD supervisor) for the excellent training in protein chemistry, to Edmond Fischer (my postdoctoral advisor) for introducing me to the field of reversible protein phosphorylation and to Peter Garland, who recruited me to Dundee and created

the atmosphere that allowed my early work to flourish. I would also like to thank the British Diabetic Association, the Louis-Jeantet Foundation, the MRC and the Royal Society for the financial support which made these studies possible.

REFERENCES

- Ahmed, N. N., Grimes, H. L., Bellacosa, A., Chan, T. O. & Tsichlis, P. N. 1997 Transduction of interleukin-2 anti-apoptotic and proliferative signals via Akt protein kinase. *Proc. Natl Acad. Sci. USA* **94**, 3627–3632.
- Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase *in vitro* and *in vivo*. *J. Biol. Chem.* **270**, 27489–27494.
- Alessi, D. R., Andjelkovic, M., Caudwell, F. B., Cron, P., Morrice, N., Cohen, P. & Hemmings, B. A. 1996a Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* **15**, 6541–6551.
- Alessi, D. R., Caudwell, F. B., Andjelkovic, M., Hemmings, B. A. & Cohen, P. 1996b Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett.* **399**, 333–338.
- Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B. & Cohen, P. 1997a Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α . *Curr. Biol.* **7**, 261–269.
- Alessi, D. R. (and 11 others) 1997b 3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the *Drosophila* DSTPK61 kinase. *Curr. Biol.* **7**, 776–789.
- Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N. & Avruch, J. 1998 3-phosphoinositide dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase *in vivo* and *in vitro*. *Curr. Biol.* **8**, 69–81.
- Andjelkovic, M., Jacubowicz, T., Cron, P., Mong, X.-F., Han, J.-W. & Hemmings, B. A. 1996 Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. *Proc. Natl Acad. Sci. USA* **93**, 5699–5704.
- Andjelkovic, M. (and 9 others) 1997 Role of translocation in the activation and function of protein kinase B. *J. Biol. Chem.* **272**, 31515–31514.
- Badger, A. M., Bradbeer, J. M., Votta, B., Lee, J. C., Adams, J. L. & Griswold, D. E. 1996 Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. *J. Pharm. Exp. Ther.* **279**, 1458–1461.
- Barthel, A., Kohn, A. D., Luo, Y. N. & Roth, R. A. 1997 A constitutively active version of the Ser/Thr kinase Akt induces production of the ob gene product, leptin, in 3T3-L1 adipocytes. *Endocrinology* **133**, 3559–3562.
- Bellacosa, A., Testa, J. R., Staal, S. P. & Tsichlis, P. N. 1991 A retroviral oncogene, AKT, encoding a serine-threonine kinase containing an SH2-like region. *Science* **254**, 244–247.
- Bellacosa, A. (and 14 others) 1995 Molecular alterations of the Akt2 oncogene in ovarian and breast carcinomas. *Int. J. Cancer* **64**, 280–285.
- Bliska, J. B., Guan, K., Dixon, J. E. & Falkow, S. 1991 Tyrosine phosphate hydrolysis of host proteins by an essential *Yersinia* virulence determinant. *Proc. Natl Acad. Sci. USA* **88**, 1187–1191.
- Burgering, B. M. Th. & Coffey, P. J. 1995 Protein-kinase-B (c-AKT) in phosphatidylinositol-3-OH kinase signal-transduction. *Nature* **376**, 599–602.
- Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N. & Testa, J. R. 1992 AKT2, a putative oncogene encoding a member of a subfamily or protein-serine threonine kinases, is amplified in human ovarian carcinomas. *Proc. Natl Acad. Sci. USA* **89**, 9267–9271.
- Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K. & Testa, J. R. 1996 Amplification of Akt2 in human pancreatic-cancer cells and inhibition of ATK2 expression and tumorigenicity by antisense. *Proc. Natl Acad. Sci. USA* **93**, 3636–3641.
- Chung, J., Kuo, C. J., Crabtree, G. R. & Blenis, J. 1992 Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 KD S6 protein-kinases. *Cell* **69**, 1227–1236.
- Coffey, P. J. & Woodgett, J. R. 1991 Molecular-cloning and characterization of a novel putative protein-serine kinase related to the cAMP-dependent and protein-kinase-C families. *Eur. J. Biochem.* **201**, 475–481.
- Cohen, P. 1978 The role of cyclic-AMP-dependent protein kinase in the regulation of glycogen metabolism in mammalian skeletal muscle. *Curr. Top. Cell Regul.* **14**, 117–196.
- Cohen, P. 1980 The role of calcium ions, calmodulin and troponin in the regulation of phosphorylase kinase from rabbit skeletal muscle. *Eur. J. Biochem.* **111**, 563–574.
- Cohen, P. 1982 The role of protein phosphorylation in neural and hormonal control of cellular activity. *Nature* **296**, 613–620.
- Cohen, P. 1985 The role of protein phosphorylation in the hormonal control of enzyme activity. *Eur. J. Biochem.* **151**, 439–444.
- Cohen, P. 1997 The search for physiological substrates of MAP and SAP kinases in mammalian cells. *Trends Cell Biol.* **7**, 353–361.
- Cohen, P., Holmes, C. F. B. & Tsukitani, Y. 1990 Okadaic acid: a new probe for the study of cellular regulation. *Trends Biochem. Sci.* **15**, 98–102.
- Craig, J. W. & Lerner, J. 1964 Influence of epinephrine and insulin on uridine diphosphate glucose- α -glucan transferase and phosphorylase in muscle. *Nature* **202**, 971–973.
- Cross, D. A. E., Alessi, D. R., Vandenheede, J. R., McDowell, H. E., Hundal, H. S. & Cohen, P. 1994 The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. *Biochem. J.* **303**, 15–20.
- Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovic, M. & Hemmings, B. A. 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* **378**, 785–788.
- Cross, D. A. E., Watt, P. W., Shaw, M., Van der Kaay, J., Downes, C. P., Holder, J. & Cohen, P. 1997 Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. *FEBS Lett.* **406**, 211–215.
- Currie, R. A., Walker, K. S., Gray, A., Deak, M., Casamayor, A., Downes, C. P., Cohen, P., Alessi, D. R. and Lucocq, J. 1999 The role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localisation of 3-phosphoinositide dependent protein kinase-1. *Biochem. J.* (In the press.)
- Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H. A., Gotoh, Y. & Greenberg, M. E. 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* **91**, 231–241.
- Deprez, J., Vertommen, D., Alessi, D. R., Hue, L. & Rider, M. H. 1997 Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase-B and other protein kinases of the insulin signalling cascades. *J. Biol. Chem.* **272**, 17269–17275.
- Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. *Proc. Natl Acad. Sci. USA* **92**, 7686–7689.

- Egloff, M. E., Johnson, D. F., Moorhead, G., Cohen, P. T. W., Cohen, P. & Barford, D. 1997 Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. *EMBO J.* **16**, 1876–1887.
- Eldar-Finkelstein, H. & Krebs, E. G. 1997 Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. *Proc. Natl Acad. Sci. USA* **94**, 9660–9664.
- Embi, N., Rylatt, D. B. & Cohen, P. 1980 Glycogen synthase kinase-3 from rabbit skeletal muscle. *Eur. J. Biochem.* **107**, 519–527.
- Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R. & Tsichlis, P. N. 1995 The protein-kinase encoded by the AKT protooncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* **81**, 727–736.
- Friedman, D. L. & Larner, J. 1963 Studies on UDPG- α -glucan transglucosylase. III. Interconversion of two forms of muscle UDPG- α -glucan transglucosylase by a phosphorylation-dephosphorylation reaction sequence. *Biochemistry* **2**, 669–675.
- Hajdich, E., Alessi, D. R., Hemmings, B. A. & Hundal, H. 1998 Expression of a membrane targetted protein kinase B α in L6 rat muscle cells promotes glucose and system A amino acid transport, protein synthesis and GSK3 inactivation. *Diabetes*. (In the press.)
- Hubbard, M. J. & Cohen, P. 1993 On target with a new mechanism for the regulation of protein phosphorylation. *Trends Biochem. Sci.* **18**, 172–177.
- Hughes, K., Ramakrishna, S., Benjamin, W. B. & Woodgett, J. R. 1992 Identification of multifunctional ATP-citrate lyase kinase as the α -isoform of glycogen synthase kinase-3. *Biochem. J.* **288**, 309–314.
- Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F. & Woodgett, J. R. 1993 Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. *EMBO J.* **12**, 803–808.
- James, S. R., Downes, C. P., Gigg, R., Grove, S. J. A., Holmes, A. B. & Alessi, D. R. 1996 Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. *Biochem. J.* **315**, 709–713.
- Jefferies, H. B. J., Reinhard, C., Kozma, S. C. & Thomas, G. A. 1994 Rapamycin selectively represses translation of the polypyrimidine tract mRNA family. *Proc. Natl Acad. Sci. USA* **91**, 4441–4445.
- Jones, P. F., Jacobowicz, T., Pitossi, F. J., Maurer, F. & Hemmings, B. A. 1991 Molecular cloning of a second form of rac protein kinase. *Proc. Natl Acad. Sci. USA* **88**, 4171–4175.
- Kasuga, M., Karlsson, F. A. & Kahn, C. R. 1982 Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. *Science* **215**, 185–187.
- Kohn, A. D., Summers, S. A., Birnbaum, M. J. & Roth, R. A. 1996 Expression of a constitutively active akt ser/thr kinase in 3T3-L1 adipocytes stimulates glucose-uptake and glucose-transporter-4 translocation. *J. Biol. Chem.* **271**, 31372–31378.
- Lefebvre, V., Mechin, M. C., Louckx, M. P., Rider, M. H. & Hue, L. 1996 Signaling pathway involved in the activation of heart 6-phosphofructo-2-kinase by insulin. *J. Biol. Chem.* **271**, 22289–22292.
- Leung, T., Chen, X. Q., Manser, E. & Lim, L. 1996 The p160 RhoA-binding kinase ROK- α is a member of a kinase family and is involved in the reorganization of the cytoskeleton. *Mol. Cell. Biol.* **16**, 5313–5327.
- Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I. & Schreiber, S. L. 1991 Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* **66**, 807–815.
- MacKintosh, C. & MacKintosh, R. W. 1994 Inhibitors of protein kinases and phosphatases. *Trends Biochem. Sci.* **19**, 444–448.
- MacKintosh, C., Beattie, K. A., Klumpp, S., Cohen, P. & Codd, G. A. 1990 Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. *FEBS Lett.* **264**, 187–192.
- MacKintosh, R. W., Dalby, K. N., Campbell, D. G., Cohen, P. T. W., Cohen, P. & MacKintosh, C. 1995 The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. *FEBS Lett.* **371**, 236–240.
- Marte, B. M. & Downward, J. 1997 PKB/Akt: connecting PI3-kinase to cell survival and beyond. *Trends Biochem. Sci.* **22**, 355–358.
- Meier, R., Alessi, D. R., Cron, P. & Hemmings, B. A. 1997 Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B β . *J. Biol. Chem.* **272**, 30491–30497.
- Myers, M. G., Sun, X.-J. & White, M. F. 1994 The IRS-1 signaling system. *Trends Biochem. Sci.* **19**, 289–293.
- Nakielnny, S., Campbell, D. G. & Cohen, P. 1991 The molecular mechanism by which adrenalin inhibits glycogen synthesis. *Eur. J. Biochem.* **199**, 713–722.
- Newton, A. C. 1995 Protein-kinase-C—structure, function, and regulation. *J. Biol. Chem.* **270**, 28495–28498.
- Nimmo, H. G. & Cohen, P. 1974 Glycogen synthase kinase 2 (GSK2); the identification of a new protein kinase in skeletal muscle. *FEBS Lett.* **47**, 62–67.
- Parker, P. J., Caudwell, F. B. & Cohen, P. 1983 Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues *in vivo*. *Eur. J. Biochem.* **130**, 227–234.
- Pawson, A. & Gish, G. D. 1992 SH2 and SH3 domains: from structure to function. *Cell* **71**, 359–362.
- Poulter, L., Ang, S. G., Gibson, B. W., Williams, D. H., Holmes, C. F. B., Caudwell, F. B., Pitcher, J. & Cohen, P. 1988 Analysis of the *in vivo* phosphorylation state of rabbit skeletal muscle glycogen synthase by fast-atom-bombardment mass spectrometry. *Eur. J. Biochem.* **175**, 497–510.
- Pullen, N. & Thomas, G. 1997 The modular phosphorylation and activation of p70(S6K). *FEBS Lett.* **410**, 78–82.
- Robison, G. A., Butcher, R. W. & Sutherland, E. W. 1971 In *Cyclic AMP*. New York and London: Academic Press.
- Rylatt, D. H., Aitken, A., Bilham, J., Condon, G. D. & Cohen, P. 1980 Glycogen synthase from rabbit skeletal muscle. *Eur. J. Biochem.* **107**, 529–537.
- Schlender, K. K., Wei, S. H. & Villar-Palasi, C. 1969 UDP-glucose: glycogen α -4-glucosyltransferase I kinase activity of purified muscle protein kinase. Cyclic nucleotide specificity. *Biochim. Biophys. Acta* **191**, 272–278.
- Shaw, M., Cohen, P. & Alessi, D. R. 1997 Further evidence that the inhibition of glycogen synthase kinase-3 β by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. *FEBS Lett.* **416**, 3–10.
- Soderling, T. R., Hickenbottom, J. P., Reimann, E. M., Hunkeler, F. L., Walsh, D. A. & Krebs, E. G. 1970 Inactivation of glycogen synthetase and activation of phosphorylase kinase by muscle adenosine 3', 5'-monophosphate-dependent protein kinases. *J. Biol. Chem.* **245**, 6317–6328.
- Stewart, A. A., Ingebritsen, T. S., Manalan, A., Klee, C. B. & Cohen, P. 1982 Discovery of a Ca^{2+} - and calmodulin-dependent protein phosphatase. *FEBS Lett.* **137**, 80–84.
- Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B. & Painter, G. F. 1997 Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* **277**, 567–570.
- Sun, X.-J. (and 8 others) 1995 Role of IRS-2 in insulin and cytokine signalling. *Nature* **377**, 173–177.
- Sutherland, C. & Cohen, P. 1994 The α -isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 *in vitro*. *FEBS Lett.* **338**, 37–42.

- Sutherland, C., Leighton, I. A. & Cohen, P. 1993 Inactivation of glycogen synthase kinase-3 β by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem. J.* **196**, 15–19.
- Ui, M., Okada, T., Hazeki, K. & Hazeki, O. 1995 Wortmannin as a unique probe for an intracellular signalling protein-phosphoinositide 3-kinase. *Trends Biochem. Sci.* **20**, 303–307.
- Ushiro, H. & Cohen, S. 1980 Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. *J. Biol. Chem.* **255**, 8363–8365.
- Vanhaesbroeck, B., Leevers, S. J., Panayotov, G. & Waterfield, M. D. 1997 Phosphoinositide 3 kinases: a conserved family of signal transducers. *Trends Biochem. Sci.* **22**, 267–282.
- Vlahos, C. J., Matter, W. F., Hui, K. Y. & Brown, R. F. 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J. Biol. Chem.* **269**, 5241–5248.
- Walker, K. S., Deak, M., Paterson, A., Hudson, K., Cohen, P. & Alessi, D. R. 1998 Activation of the PKB β and PKB γ isoforms by insulin *in vivo* and PDK1 *in vitro*: comparison with PKB α . *Biochem. J.* **331**, 299–308.
- Walsh, D. A., Perkins, J. P. & Krebs, E. G. 1968 An adenosine 3',5'-monophosphate-dependent protein kinase from rabbit skeletal muscle. *J. Biol. Chem.* **243**, 3763–3765.
- Welsh, G. I. & Proud, C. G. 1993 Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. *Biochem. J.* **294**, 625–629.
- Whitman, M., Downes, C. P., Keeler, M., Keller, T. & Cantley, L. C. 1988 Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. *Nature* **332**, 644–646.
- Wijkander, J., Holst, L. S., Rahn, T., Resjo, S., Castan, I., Mangianello, V., Belfrage, P. & Degerman, E. 1997 Regulation of protein kinase B in rat adipocytes by insulin, vanadate, and peroxovanadate—membrane translocation in response to peroxovanadate. *J. Biol. Chem.* **272**, 21520–21526.
- Woscholski, R. & Parker, P. J. 1997 Inositol lipid 5-phosphatases—traffic signals and signal traffic. *Trends Biochem. Sci.* **22**, 427–431.